[Featured Stock] NSN Rises on Bill Proposed to Support Overcoming Depression Due to Corona Blue

[Asia Economy Reporter Jang Hyowon] As a bill supporting the overcoming of depression and anxiety disorders caused by the novel coronavirus infection (hereinafter COVID-19) has been proposed, the stock price of NSN, which is developing treatment devices for depression, is rising.

As of 10:15 a.m. on the 2nd, NSN is trading at 1,820 won, up 4.9% compared to the previous trading day.

On the 30th of last month, Yang Gidae, a member of the National Assembly from the Democratic Party of Korea (Gyeonggi Gwangmyeong), took the lead in proposing a partial amendment to the Act on Mental Health Promotion and Welfare Services for Mental Patients (Mental Health Welfare Act). The amendment includes legal grounds for psychological treatment support for citizens suffering from depression and anxiety due to COVID Blue.

As the prolonged COVID-19 pandemic has increased the number of citizens complaining of depression and anxiety disorders, NSN, which is developing and conducting clinical trials of brain disease treatment devices related to depression through its subsidiary Neurosona, is being recognized as a related stock.

Neurosona, a specialized brain disease treatment device company, is jointly conducting exploratory clinical trials on brain stimulation treatment for depression brain function regulation using its self-developed brain disease treatment device ‘Neurosona (NEUROSONA)’ with Professor Seok Jeongho of Gangnam Severance Hospital, Yonsei University College of Medicine.

In the recent interim results of the exploratory clinical trial on depression announced by Professor Seok Jeongho, it was found that using ‘Neurosona (NEUROSONA)’ significantly improved the symptoms of patients with depression.